We are live on
!
Find out more
RCM
RA Capital Management Portfolio holdings
AUM
$11.5B
1-Year Est. Return
168.77%
This Fund
S&P 500
This Quarter
Est. Return
-11.64%
1 Year Est. Return
+168.77%
3 Year Est. Return
+596.08%
5 Year Est. Return
+846.46%
10 Year Est. Return
+54,223.74%
AUM
$782M
AUM Growth
-$228M
(-23%)
Cap. Flow
+$27.9M
Cap. Flow
% of AUM
3.57%
Top 10 Holdings %
Top 10 Hldgs %
64.89%
Holding
44
New
7
Increased
12
Reduced
6
Closed
2
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nektar Therapeutics
NKTR
|
+$40.7M |
| 2 |
AVXS
AveXis, Inc. Common Stock
AVXS
|
+$29.8M |
| 3 |
ACOR
Acorda Therapeutics
ACOR
|
+$17.2M |
| 4 |
Ardelyx
ARDX
|
+$17M |
| 5 |
TG Therapeutics
TGTX
|
+$15M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
DYAX
DYAX CORPORATION
DYAX
|
+$102M |
| 2 |
RGLS
Regulus Therapeutics
RGLS
|
+$16.2M |
| 3 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
+$14.8M |
| 4 |
BPMC
Blueprint Medicines
BPMC
|
+$14.3M |
| 5 |
Collegium Pharmaceutical
COLL
|
+$6.75M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 96.67% |
| 2 | Miscellaneous | 3.33% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Wave Life Sciences
WVE
$879M
| $98.4M | 12.58% |
7,088,651
| – | – |
|
|
ACHN
2
DELISTED
Achillion Pharmaceuticals
ACHN
| $92.9M | 11.87% |
12,033,220
+810,327
| +7% | +$5.93M |
|
|
SIOX
3
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
| $57.4M | 7.34% |
625,000
| – | – |
|
4
Aclaris Therapeutics
ACRS
$814M
| $49.8M | 6.36% |
2,627,719
+63,166
| +2% | +$1.21M |
|
|
5
Nektar Therapeutics
NKTR
$2.28B
| $43.7M | 5.59% |
+211,924
| New | +$40.7M |
|
6
Ascendis Pharma A/S
ASND
$15.8B
| $40.1M | 5.12% |
2,161,366
+489,919
| +29% | +$8.7M |
|
|
7
TG Therapeutics
TGTX
$8.12B
| $38.6M | 4.94% |
4,531,714
+1,717,935
| +61% | +$15M |
|
|
AVXS
8
DELISTED
AveXis, Inc. Common Stock
AVXS
| $37.1M | 4.74% |
+1,361,582
| New | +$29.8M |
|
9
Coherus Oncology
CHRS
$205M
| $27M | 3.45% |
1,272,048
| – | – |
|
|
ZGNX
10
DELISTED
Zogenix, Inc.
ZGNX
| $22.6M | 2.9% |
2,451,237
+198,000
| +9% | +$1.98M |
|
|
ARNA
11
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $18.4M | 2.36% |
936,411
+64,963
| +7% | +$1.04M |
|
|
12
Ardelyx
ARDX
$878M
| $17.9M | 2.28% |
2,300,481
+1,729,037
| +303% | +$17M |
|
|
AIMT
13
DELISTED
Aimmune Therapeutics
AIMT
| $17.5M | 2.24% |
1,292,940
+502,740
| +64% | +$7.84M |
|
|
CPXX
14
DELISTED
CELATOR PHARMACEUTICALS INC. COMMON STOCK
CPXX
| $15.6M | 1.99% |
+1,414,114
| New | +$4.64M |
|
15
Neurogene
NGNE
$674M
| $14.9M | 1.91% |
84,599
+3,600
| +4% | +$700K |
|
|
CDTX
16
DELISTED
Cidara Therapeutics
CDTX
| $14.9M | 1.91% |
58,711
| – | – |
|
|
SGMO
17
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $13.4M | 1.71% |
2,212,036
| – | – |
|
|
ACOR
18
DELISTED
Acorda Therapeutics
ACOR
| $13.2M | 1.68% |
+4,151
| New | +$17.2M |
|
|
DRNA
19
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $13M | 1.66% |
2,428,571
| – | – |
|
20
Protara Therapeutics
TARA
$222M
| $12.6M | 1.61% |
40,673
+3,750
| +10% | +$1.21M |
|
|
SBBP
21
DELISTED
Strongbridge Biopharma plc.
SBBP
| $12.3M | 1.57% |
2,690,702
| – | – |
|
|
DMTX
22
DELISTED
Dimension Therapeutics, Inc
DMTX
| $12.1M | 1.55% |
1,548,033
+460,103
| +42% | +$3.62M |
|
23
Arcturus Therapeutics
ARCT
$450M
| $11.5M | 1.47% |
433,273
| – | – |
|
|
VTAE
24
DELISTED
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
| $10.4M | 1.33% |
1,575,000
+1,253,839
| +390% | +$11.4M |
|
|
25
Collegium Pharmaceutical
COLL
$711M
| $8.83M | 1.13% |
486,557
-371,126
| -43% | -$6.75M |
|
Similar funds
AAIS
MG
CC
AI
BMSSC
HTC
WAM
RA Capital Management's Q1 2016 Portfolio in Review
As of Q1 2016, RA Capital Management held 44 positions worth $782M, down 23% from $1.01B the previous quarter. Its ten largest holdings account for 65% of the portfolio.
RA Capital Management deployed $27.9M of net new capital in Q1 2016, opening 7 new positions and adding to 12 existing holdings. Its largest new stake was Nektar Therapeutics: 211,924 shares worth $43.7M.
By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 89% a quarter earlier, followed by Miscellaneous.
On the sell side, the largest reduction was Regulus Therapeutics, an estimated $16.2M trimmed.
- RA Capital Management's largest Q1 2016 buy was Nektar Therapeutics: 211,924 shares worth $43.7M.
- RA Capital Management added most to Ardelyx in Q1 2016, an estimated $17M increase.
- RA Capital Management's biggest Q1 2016 reduction was Regulus Therapeutics, cutting an estimated $16.2M.
- RA Capital Management fully exited DYAX CORPORATION in Q1 2016, selling an estimated $102M.
- RA Capital Management's ten largest holdings make up 65% of its $782M portfolio in Q1 2016.
- RA Capital Management opened 7 new positions and closed 2 in Q1 2016.
- RA Capital Management's portfolio value fell 23% quarter-over-quarter to $782M.
Based on RA Capital Management's 13F filing for Q1 2016, filed 16 May 2016.